Jul 11, 2025 | Cost Savings, Drug advertising, Drug costs, Health care costs, High-value formulary, MedBen Rx, Pharmacy, Rx Costs, Spending
Pharmaceutical advertising hit a record high in 2024, with the top 10 drugs accounting for $3.3 billion in ad spending – up nearly 20% from the previous year. With more campaigns directly targeting consumers, MedBen Rx’s high-value formulary educates members about...
Jul 10, 2025 | Cost Savings, Health care costs, Trend
Per Fierce Healthcare: “A new report from federal actuaries estimates national health spending will increase by 7.1% in 2025, with spending growth set to outpace growth in the U.S. gross domestic product.” Historically, MedBen clients have maintained a cost trend...
Jun 27, 2025 | Cost management, Cost Savings, Discounts, Forensic claims review, Health care costs, Savings
The 2025 MedBen Client Report highlights how our proven self-funding solutions have consistently helped employers control health care costs. One of the most impactful tools – forensic claims review – was introduced in 2007 and continues to deliver measurable value,...
Mar 25, 2025 | Alternative Reimbursement Strategies, Cost Savings, Discounts, Fair market reimbursement, Health care costs
MedBen clients who used Fair Market Reimbursement in 2024 yielded a discount average of 56% with an appeals rate of just 0.23%. MedBen’s Fair Market Reimbursement combines the best aspects of PPOs and reference-based pricing by evaluating all types of claims to...
Mar 21, 2025 | Cost Savings, Emergency Room (ER), Family doctors, Health care costs, Primary Care, Urgent Care
For MedBen clients in 2024, 15% of emergency room visits were potentially avoidable… typically for conditions that could have been better managed in a more cost-effective setting. A visit to an urgent care facility or family doctor can save a plan member, on average,...
Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
